Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Rogai

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
PPAR Research|September 22, 2012
PPARγ in Inflammatory Bowel DiseaseVito Annese, Francesca Rogai, Alessia Settesoldi, et al.
Expert Review of Gastroenterology & Hepatology|January 14, 2014
Ustekinumab: moving the target from psoriasis to Crohn's diseaseAlessia Settesoldi, Manuela Coppola, Francesca Rogai, et al.
Clinical Journal of Gastroenterology|September 13, 2018
Golimumab in inflammatory bowel diseases: present and future scenariosGabriele Dragoni, Marco Le Grazie, Beatrice Orlandini, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 11, 2013
Mucosal healing in inflammatory bowel disease: treatment efficacy and predictive factorsClaudio Papi, Federica Fascì-Spurio, Francesca Rogai, et al.
Journal of Digestive Diseases|July 25, 2018
Clinical efficacy and safety of golimumab in biologically experienced and naive patients with active ulcerative colitis: A real-life experience from two Italian IBD centersBeatrice Orlandini, Gabriele Dragoni, Angela Variola, et al.
Inflammatory Bowel Diseases|April 23, 2016
Disease Course and Colectomy Rate of Ulcerative Colitis: A Follow-up Cohort Study of a Referral Center in TuscanyNatalia Manetti, Siro Bagnoli, Francesca Rogai, et al.
Scientific Reports|February 16, 2019
A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodiesMarten Beeg, Alessandro Nobili, Barbara Orsini, et al.
Journal of Digestive Diseases|March 31, 2019
Long-term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real-life experience from a tertiary referral centerGabriele Dragoni, Siro Bagnoli, Marco Le Grazie, et al.
European Journal of Gastroenterology & Hepatology|January 20, 2022
Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel diseaseTommaso Innocenti, Jenny Roselli, Erica N Lynch, et al.
Journal of Digestive Diseases|September 26, 2022
Pregnancy outcomes in inflammatory bowel disease: Data from a large cohort surveyTommaso Innocenti, Jenny Roselli, Alice Taylor, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
PPAR Research|September 22, 2012
PPARγ in Inflammatory Bowel DiseaseVito Annese, Francesca Rogai, Alessia Settesoldi, et al.
Expert Review of Gastroenterology & Hepatology|January 14, 2014
Ustekinumab: moving the target from psoriasis to Crohn's diseaseAlessia Settesoldi, Manuela Coppola, Francesca Rogai, et al.
Clinical Journal of Gastroenterology|September 13, 2018
Golimumab in inflammatory bowel diseases: present and future scenariosGabriele Dragoni, Marco Le Grazie, Beatrice Orlandini, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 11, 2013
Mucosal healing in inflammatory bowel disease: treatment efficacy and predictive factorsClaudio Papi, Federica Fascì-Spurio, Francesca Rogai, et al.
Journal of Digestive Diseases|July 25, 2018
Clinical efficacy and safety of golimumab in biologically experienced and naive patients with active ulcerative colitis: A real-life experience from two Italian IBD centersBeatrice Orlandini, Gabriele Dragoni, Angela Variola, et al.
Inflammatory Bowel Diseases|April 23, 2016
Disease Course and Colectomy Rate of Ulcerative Colitis: A Follow-up Cohort Study of a Referral Center in TuscanyNatalia Manetti, Siro Bagnoli, Francesca Rogai, et al.
Scientific Reports|February 16, 2019
A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodiesMarten Beeg, Alessandro Nobili, Barbara Orsini, et al.
Journal of Digestive Diseases|March 31, 2019
Long-term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real-life experience from a tertiary referral centerGabriele Dragoni, Siro Bagnoli, Marco Le Grazie, et al.
European Journal of Gastroenterology & Hepatology|January 20, 2022
Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel diseaseTommaso Innocenti, Jenny Roselli, Erica N Lynch, et al.
Journal of Digestive Diseases|September 26, 2022
Pregnancy outcomes in inflammatory bowel disease: Data from a large cohort surveyTommaso Innocenti, Jenny Roselli, Alice Taylor, et al.
Pageof 3